IDH状态是预测新诊断间变性胶质瘤预后的唯一因素吗?单中心大样本结局评估与预后因素分析
该单中心回顾性分析纳入142例间变性胶质瘤患者,评估除IDH状态外影响生存的预后因素。结果显示,除分子分型外,切除程度(EOR)和残瘤体积(RTV)也显著影响生存(p<0.0001),序贯放化疗是更有效的辅助治疗。
要点
- 除IDH状态外,切除程度和残瘤体积也独立影响间变性胶质瘤患者生存。
- 序贯放化疗是所评估的辅助治疗方案中更有效的一种。
- 无论肿瘤特征如何,辅助放疗在所有间变性胶质瘤患者中均具关键作用。
核心结论
- 除IDH状态外,切除程度和残瘤体积统计学上显著影响间变性胶质瘤患者生存。
- 辅助放疗在所有间变性胶质瘤患者中均具关键作用,与肿瘤特征无关。
研究设计与样本
- 单中心回顾性分析,从402例间变性胶质瘤患者中纳入142例具备临床、影像和分子数据且可手术者。
- 切除程度分为全切、近全切、次全切和部分切除,并量化残瘤体积。
主要发现
- 中位无进展生存期35个月(95%CI 27-76),1年、3年、5年无进展生存率分别为78.9%±3.4%、49.7%±4.6%、42.7%±5.4%。
- 中位总生存期91个月(95%CI 66-95),1年、3年、5年总生存率分别为90.1%±2.5%、70.9%±4.2%、61.8%±4.9%。
- 除分子分型外,预测生存的预后因素为切除程度和残瘤体积(p<0.0001)。
- 序贯放化疗是更有效的辅助治疗。
关键数值与推荐
- 全切在超过半数患者(56.3%)中实施,83例(58.5%)检测到残瘤。
- 67.6%为IDH突变型,71.8%为MGMT启动子甲基化。
- 50.7%接受放疗联合同期及辅助替莫唑胺,33.8%接受序贯放化疗,15.5%仅接受辅助化疗。
临床怎么用
- 在IDH状态之外,应关注切除程度和残瘤体积对预后的影响。
- 辅助放疗应视为所有间变性胶质瘤患者的关键治疗组成部分。
- 序贯放化疗可作为更有效的辅助治疗选择之一。
局限性
- 单中心回顾性设计可能引入选择偏倚。
- 仅纳入可手术且具备完整临床、影像和分子数据的患者,可能存在选择限制。
- 样本来自402例中的142例,非全体间变性胶质瘤人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Anaplastic gliomas (AGs) are an extremely heterogeneous group of primary brain tumors. More recently, new discoveries have indicated that isocitrate dehydrogenase (IDH) mutation status is the most important parameter predicting survival. The primary aim of the present analysis was to identify prognostic factors, other than IDH status, that eventually impact survival. METHODS: Patients with available clinical, imaging, and molecular profile data who were amenable to resection were evaluated. The extent of resection (EOR) was defined as gross-total resection (GTR), near-total resection (NTR), subtotal resection (STR), or partial resection (PR). Residual tumor volume (RTV) was quantified. Following surgery, patients received adjuvant chemotherapy alone, radiation therapy plus concomitant and adjuvant temozolomide (TMZ), or sequential radio-chemotherapy. Clinical outcome was evaluated by neurological examination and MRI 1 month after treatment and every 4 months thereafter. Tumor progression was defined according to the Response Assessment in Neuro-Oncology (RANO) working group. RESULTS: Among 402 patients referred to the authors' institution for AG, 142 were included in the present analysis. Eighty-eight (62%) were male and 54 (38%) were female, with a median age of 43 years (range 19-70 years). At admission, most patients had a Karnofsky Performance Scale score of 90-100 (84.5%) and were symptomatic (93.7%). Forty-eight (33.8%) patients had newly diagnosed anaplastic oligodendrogliomas (AOs), and 94 (66.2%) had anaplastic astrocytomas (AAs). Most of them had mutant IDH tumors (67.6%) and methylated O 6-methylguanine-DNA-methyltransferase (MGMT) promoter status (71.8%). GTR was performed in more than half of the patients (56.3%). RTV was detected in 83 (58.5%) patients. Following surgery, 72 (50.7%) patients received radiotherapy with concomitant and adjuvant TMZ, 48 (33.8%) received sequential radio-chemotherapy, and 22 (15.5%) received adjuvant chemotherapy alone. The median follow-up time was 40 months (range 16-146 months). The median PFS time and the 1-, 3-, and 5-year PFS rates were 35 months (95% CI 27-76) and 78.9% ± 3.4%, 49.7% ± 4.6%, and 42.7% ± 5.4%, respectively. The median OS time and the 1-, 3-, and 5-year OS rates were 91 months (95% CI 66-95) and 90.1% ± 2.5%, 70.9% ± 4.2%, and 61.8% ± 4.9%, respectively. Prognostic factors predicting survival other than molecular profile were the EOR and the RTV (p < 0.0001). Sequential radio-chemotherapy was the more effective treatment administered. CONCLUSIONS: In addition to IDH status, EOR and the RTV have proved to statistically impact survival. The pivotal role of adjuvant radiotherapy has been recorded in all AG patients, regardless of tumor features.
引用
- Navarria P, Pessina F, Clerici E, et al. Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series. J Neurosurg. 2020. PMID: 32886916. doi:10.3171/2020.5.JNS201116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。